ACC 2020 This post-hoc analysis showed an association between increased Lp(a) and increased risk of aortic stenosis events. Evolocumab reduced risk of aorta stenosis after 1-year treatment.

ACC 2020 This trial showed that evolocumab treatment of dyslipidemic people living with HIV reduced LDL-c and other atherogenic lipids and lipoproteins and was well tolerated and safe.

ACC 2020 This analysis showed that a genetic risk score predicts VTE risk in patients with cardiometabolic disease and that evolocumab reduces the risk for VTE in patients in the top 1/3 of genetic risk.

ACC 2020 This post-hoc analysis of the DAPA-HF trial showed a consistent treatment benefit of dapagliflozin in HFrEF patients compared with placebo, regardless of background therapy.

ACC 2020 This subgroup analysis of the VOYAGER PAD trial demonstrated that addition of clopidogrel to rivaroxaban and aspirin has no added benefit in PAD patients undergoing revascularization, but may increase ISTH major bleeding.

ACC 2020 Ticagrelor monotherapy after 3-months DAPT reduces net adverse clinical events compared with continued DAPT in ACS patients who underwent PCI with drug-eluting stents (DES).

ACC 2020 Dirk Blom discusses the design and outcomes of the ODYSSEY HoFH trial, evaluating LDL-c lowering and safety of alirocumab in HoFH patients.

ACC 2020 This pre-specified secondary analysis of the DAPA-HF trial showed that dapagliflozin reduces the risk of first and recurrent HF hospitalizations compared with placebo.

ACC 2020 Jonathan Cunningham shares three major findings from a subanalysis of the PARAGON-HF trial in HFpEF patients.

ACC 2020 A subanalysis of the PARAGON-HF trial demonstrated that treatment with the ARNI sacubitril/valsartan reduced NT-proBNP levels with 19% compared to valsartan alone in HFpEF.

ACC 2020 George Dangas discusses the safety and efficacy results of the TWILIGHT-COMPLEX post-hoc study and compares the results with those of the overall TWILIGHT trial.

ACC 2020 This trial demonstrated that smoking e-cigarettes plus counseling for 12 weeks increased smoking abstinence and decreased daily cigarette use in participants of the general population compared to counseling alone.